National Center for Complementary and Integrative Health (2022) Complementary, alternative, or integrative health: What’s in a name? National Center for Complementary and Integrative Health. https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name. Accessed 14 Sep 2022

Kappauf H, Leykauf-Ammon D, Bruntsch U, Horneber M, Kaiser G, Büschel G, Gallmeier WM (2000) Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematology. Support Care Cancer 8:314–322. https://doi.org/10.1007/s005209900111

Article  CAS  Google Scholar 

Oh B, Butow P, Mullan B, Beale P, Pavlakis N, Rosenthal D, Clarke S (2010) The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia Pac J Clin Oncol 6:342–349. https://doi.org/10.1111/j.1743-7563.2010.01329.x

Article  Google Scholar 

Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25:548–554. https://doi.org/10.1200/JCO.2005.03.9800

Article  Google Scholar 

Kumar NB, Hopkins K, Allen K, Riccardi D, Besterman-Dahan K, Moyers SJCC (2002) Use of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practice. Cancer Control 9:236–243. https://doi.org/10.1177/107327480200900307

Article  Google Scholar 

Chan WJJ, McLachlan AJ, Wheate NJ, Harnett JE (2018) An evaluation of garlic products available in Australian pharmacies–from the label to the laboratory. J Herb Med 14:61–67. https://doi.org/10.1016/j.hermed.2018.09.004

Article  Google Scholar 

Cohen M, Hunter J (2017) Complementary medicine products: interpreting the evidence base. Intern Med J 47:992–998. https://doi.org/10.1111/imj.13534

Article  Google Scholar 

Barnes J (2003) Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality. Br J Clin Pharmacol 55:226–233. https://doi.org/10.1046/j.1365-2125.2003.01810.x

Article  Google Scholar 

Carmona F, Pereira AMS (2013) Herbal medicines: old and new concepts, truths and misunderstandings. Rev Bras Farmacogn 23:379–385. https://doi.org/10.1590/S0102-695X2013005000018

Article  Google Scholar 

Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD (2004) Herb-drug interactions: an evidence based approach. Curr Med Chem 11:1513–1525. https://doi.org/10.2174/0929867043365198

Article  CAS  Google Scholar 

Niu J, Straubinger RM, Mager DE (2019) Pharmacodynamic drug-drug interactions. Clin Pharmacol Ther 105:1395–1406. https://doi.org/10.1002/cpt.1434

Article  Google Scholar 

Florence A, Attwood D (1998) Physicochemical drug interactions and incompatibilities. Physicochemical principles of pharmacy. Springer, New York, pp 449–492

Chapter  Google Scholar 

Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2009) An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 35:18–31. https://doi.org/10.1016/j.ctrv.2008.07.003

Article  CAS  Google Scholar 

Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470–481. https://doi.org/10.2174/138920009788897975

Article  CAS  Google Scholar 

Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425–461. https://doi.org/10.1124/pr.55.3.1

Article  CAS  Google Scholar 

Lin JH, Yamazaki MJCp (2003) Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet 42:59–98

Article  CAS  Google Scholar 

Saneja A, Khare V, Alam N, Dubey RD, Gupta PN (2014) Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv 11:121–138. https://doi.org/10.1517/17425247.2014.865014

Article  CAS  Google Scholar 

Stieger B, Mahdi ZM, Jäger W (2017) Intestinal and hepatocellular transporters: therapeutic effects and drug interactions of herbal supplements. Annu Rev Pharmacol Toxicol 57:399–416. https://doi.org/10.1146/annurev-pharmtox-010716-105010

Article  CAS  Google Scholar 

Dolton MJ, Roufogalis BD, McLachlan AJ (2012) Fruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptides. Clin Pharmacol Ther 92:622–630. https://doi.org/10.1038/clpt.2012.159

Article  CAS  Google Scholar 

Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ (2019) Understanding drug interactions with St John’s wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol 71:129–138. https://doi.org/10.1111/jphp.12858

Article  CAS  Google Scholar 

Rodrigues AD, Lai Y, Shen H, Varma MVS, Rowland A, Oswald S (2020) Induction of human intestinal and hepatic organic anion transporting polypeptides: where is the evidence for its relevance in drug-drug interactions? Drug Metab Dispos 48:205–216. https://doi.org/10.1124/dmd.119.089615

Article  CAS  Google Scholar 

Greenblatt DJ (2017) Mechanisms and consequences of drug-drug interactions. Clin Pharmacol Drug Dev 6:118–124. https://doi.org/10.1002/cpdd.339

Article  CAS  Google Scholar 

Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE (2020) Clinical relevance of St. John’s wort drug interactions revisited. Br J Pharmacol 177:1212–1226. https://doi.org/10.1111/bph.14936

Article  CAS  Google Scholar 

Yang J, Kjellsson M, Rostami-Hodjegan A, Tucker GT (2003) The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci 20:223–232. https://doi.org/10.1016/s0928-0987(03)00200-8

Article  CAS  Google Scholar 

Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB (2006) A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097–1105. https://doi.org/10.1093/ajcn/83.5.1097

Article  CAS  Google Scholar 

Fontana E, Dansette PM, Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413–454. https://doi.org/10.2174/138920005774330639

Article  CAS  Google Scholar 

Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF (2014) Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 42:301–317. https://doi.org/10.1124/dmd.113.055236

Article  CAS  Google Scholar 

Cox EJ, Tian DD, Clarke JD, Rettie AE, Unadkat JD, Thummel KE, McCune JS, Paine MF (2021) Modeling Pharmacokinetic natural product-drug interactions for decision-making: a NaPDI center recommended approach. Pharmacol Rev 73:847–859. https://doi.org/10.1124/pharmrev.120.000106

Article  CAS  Google Scholar 

Zhang H, Bu F, Li L, Jiao Z, Ma G, Cai W, Zhuang X, Lin HS, Shin JG, Xiang X (2018) Prediction of drug-drug interaction between tacrolimus and principal ingredients of Wuzhi Capsule in Chinese healthy volunteers using physiologically-based pharmacokinetic modelling. Basic Clin Pharmacol Toxicol 122:331–340. https://doi.org/10.1111/bcpt.12914

Article  CAS  Google Scholar 

McDonald MG, Tian DD, Thummel KE, Paine MF, Rettie AE (2020) Modulation of major human liver microsomal cytochromes P450 by Component alkaloids of goldenseal: time-dependent inhibition and allosteric effects. Drug Metab Dispos 48:1018–1027. https://doi.org/10.1124/dmd.120.091041

Article  CAS  Google Scholar 

Malki MA, Pearson ER (2020) Drug-drug-gene interactions and adverse drug reactions. Pharmacogenom J 20:355–366. https://doi.org/10.1038/s41397-019-0122-0

Article  CAS  Google Scholar 

Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, Tamai I, Tateishi T, Ohashi K (2011) The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genom 21:84–93. https://doi.org/10.1097/fpc.0b013e32834300cc

Article  CAS  Google Scholar 

Mougey EB, Lang JE, Wen X, Lima JJ (2011) Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol 51:751–760. https://doi.org/10.1177/0091270010374472

Article  CAS  Google Scholar 

Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM (2006) Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 12:4636–4640. https://doi.org/10.1158/1078-0432.CCR-06-0388

Article  CAS  Google Scholar 

Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. https://doi.org/10.1093/jncimonographs/lgh026

Article  Google Scholar 

Redvers A, Laugharne R, Kanagaratnam G, Srinivasan GJPB (2001) How many patients self-medicate with St John’s wort? Psychiatr Bull 25:254–256

Article  Google Scholar 

Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604. https://doi.org/10.1067/mcp.2000.112240

Article  Google Scholar 

Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 94:1247–1249. https://doi.org/10.1093/jnci/94.16.1247

Article  CAS  Google Scholar 

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–2194

CAS  Google Scholar 

Parvez MM, Basit A, Jariwala PB, Gáborik Z, Kis E, Heyward S, Redinbo MR, Prasad B (2021) Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation. Drug Metab Dispos 49:683–693. https://doi.org/10.1124/dmd.121.000476

Article  CAS  Google Scholar 

Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ (2004) The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24:1508–1514. https://doi.org/10.1592/phco.24.16.1508.50958

Article  CAS  Google Scholar 

Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ (2004) Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323–329. https://doi.org/10.1016/j.clpt.2004.06.007

Article  CAS  Google Scholar 

Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894. https://doi.org/10.2165/00003088-200544090-00001